| |
| . |
 980  1/66  |
|
|
제목 |
Hyundai Pharm has signed an exclusive Marketing and Distribution Agreement for Mifegymiso®, a medical abortion product |
매체 |
Hyundai Pharm |
링크 |
|
내용 |
Hyundai Pharm announced that it has signed an exclusive Marketing and Distribution agreement with UK pharmaceutical company Linepharma International for Mifegymiso®, a product indicated for medical abortion. Hyundai Pharm is in close consultation with the Ministry of Food and Drug Safety to submit the NDA as soon as possible. This product is a Combi-Pack of mifepristone and misoprostol, and has been designated as an essential medicine by the World Health Organization (WHO) (https://list.essentialmeds.org/?indication=240) and has been recognized as a safe product indicated for medical termination of a developing intra-uterine pregnancy.
A representative of Hyundai Pharm said, “There are frequent cases of illegally purchasing and taking pregnancy termination drugs on the Internet. In this case, serious side effects may occur due to inaccurate information about the dosage to take, administration method, and contraindications, etc., and sequelae may remain.” He also said, “Our decision to introduce Linepharma's medical abortion product was a choice for women's safety, and we hope that the product will be safely taken in consultation with experts in the future.”
A representative from Linepharma said “Following the legalisation of abortion in South Korea Linepharma are proud to have partnered with Hyundai Pharm, a well renowned company in Sexual and Reproductive Health, to ensure the Women in South Korea have access to safe abortion, in line with our global mission.”
About Linepharma International
Linepharma is a pharmaceutical company committed to improving Sexual and Reproductive Health through expanding access to safe medication abortion. Founded in France in 2010 by the scientific team responsible for the development of the mifepristone molecule. Linepharma, has brought medication abortion products to market in many countries around the world. Primarily servicing the Americas and Asia-Pacific regions, Linepharma is an international leader in the provision of safe non-surgical abortion products. Of the approximately 73 million induced abortions that took place each year between 2015 and 2019, an estimated 24 million were unsafe. Linepharma strives to help resolve this through bringing stringent regulatory health authority approved products to market.
https://linepharma-lab.com/
|
|
 |
 |
 |
|
